Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Chiome Bioscience Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This pending matter is assigned to 1 distinct examiner and 1 distinct art unit. The limited volume of pending actions suggests a targeted filing strategy or a specific phase of portfolio development. Practitioners should align their strategy with the specific examination standards of this 1 distinct art unit to ensure efficient handling of the matter.
The busiest examiner for this portfolio is LANDSMAN, ROBERT S, who is currently managing 1 pending office action. This single action represents the total pending workload for the company at the USPTO. Since the busiest examiner pending count is 1 and the total pending office actions is 1, the company's current prosecution success depends on the review of this individual. Practitioners should consider the specific precedents of the Biotechnology & Pharmaceuticals area when addressing the requirements of LANDSMAN, ROBERT S. The concentration of work under 1 distinct examiner allows for a highly focused prosecution approach.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030203 | MEDICINE FOR TREATING CANCER | LANDSMAN, ROBERT S | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030203 | MEDICINE FOR TREATING CANCER | LANDSMAN, ROBERT S | 23d overdue |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030203 | MEDICINE FOR TREATING CANCER | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | 23d overdue | Pending | Apr 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial